Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

Therapy resistance is a major challenge in the treatment of cancer. Here, we performed CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to identify genomic determinants of drug response. Our screens uncover a selective dependency on RNA splicing factors whose loss...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cancer cell Ročník 41; číslo 1; s. 164
Hlavní autori:	Wang, Eric, Pineda, Jose Mario Bello, Kim, Won Jun, Chen, Sisi, Bourcier, Jessie, Stahl, Maximilian, Hogg, Simon J, Bewersdorf, Jan Phillipp, Han, Cuijuan, Singer, Michael E, Cui, Daniel, Erickson, Caroline E, Tittley, Steven M, Penson, Alexander V, Knorr, Katherine, Stanley, Robert F, Rahman, Jahan, Krishnamoorthy, Gnana, Fagin, James A, Creger, Emily, McMillan, Elizabeth, Mak, Chi-Ching, Jarvis, Matthew, Bossard, Carine, Beaupre, Darrin M, Bradley, Robert K, Abdel-Wahab, Omar
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 09.01.2023
Predmet:	Apoptosis - genetics Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cell Line, Tumor Humans Leukemia, Myeloid, Acute - genetics Myeloid Cell Leukemia Sequence 1 Protein - metabolism Protein-Tyrosine Kinases Proto-Oncogene Proteins c-bcl-2 RNA Splicing - genetics RNA-Binding Proteins - genetics CLK acute myeloid leukemia BCL2 XIAP venetoclax DYRK RBM10 RNA splicing
ISSN:	1878-3686, 1878-3686
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!